

Form PTO-1449 (modified)		Atty. Docket No.: GENU:009USD1	Serial No.: 10/733,212
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant: Donald W. KUFE	
		Filing Date: December 11, 2003	Group: 1633
U.S. Patent Documents <i>See Page 1-2</i>	Foreign Patent Documents <i>See Page 2-3</i>	Other Art <i>See Page 3-23</i>	

U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.
	A1	2002/0110841	08/15/02	Kufe	435	7.23	12/26/01
	A2	2003/0148969	08/07/03	Dobie <i>et al.</i>	514	44	12/20/01
	A3	2004/0018181	01/29/04	Kufe <i>et al.</i>	424	93.21	05/29/03
	A4	2004/0166543	08/26/04	Kufe	435	7.23	12/11/03
	A5	2004/0209832	10/21/04	McSwiggen	514	44	09/23/03
	A6	2005/0053606	03/10/05	Kufe <i>et al.</i>	424	155.1	09/11/01
	A7	4,497,796	02/05/85	Salser <i>et al.</i>	514	44	12/08/82
	A8	4,675,382	06/23/87	Murphy	260	112	11/06/85
	A9	4,740,461	10/15/96	Kufe <i>et al.</i>	435	69.1	12/24/83
	A10	4,894,227	01/16/90	Stevens <i>et al.</i>	424	085.200	05/29/87
	A11	4,963,484	10/16/90	Kufe	435	069.300	01/29/88
	A12	5,053,489	10/01/91	Kufe	530	350	01/27/89
	A13	5,080,898	01/14/92	Murphy	424	94.1	02/21/89
	A14	5,380,712	01/10/95	Ballance <i>et al.</i>	514	12	02/14/92
	A15	5,506,343	04/09/96	Kufe	530	387.7	10/25/94
	A16	5,530,101	06/25/96	Queen <i>et al.</i>	530	387.3	12/19/90
	A17	5,565,334	10/17/94	Kufe <i>et al.</i>	435	69.1	10/17/94
	A18	5,612,895	03/18/97	Balaji <i>et al.</i>	702	19	04/21/95
	A19	5,766,833	06/16/98	Balance <i>et al.</i>	435	69.7	11/17/93
	A20	5,776,427	07/07/98	Thorpe <i>et al.</i>	424	1.49	06/01/95
	A21	5,801,154	09/01/98	Baracchini <i>et al.</i>	514	44	04/08/97
	A22	5,861,381	01/19/99	Chambon <i>et al.</i>	514	44	06/07/95
	A23	5,965,386	10/12/99	Kerry-Williams <i>et al.</i>	435	69.1	03/01/95

70153984.1

EXAMINER:**DATE CONSIDERED:**

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /KH/

Form PTO-1449 (modified)		Atty. Docket No.: GENU:009USD1	Serial No.: 10/733,212
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant: Donald W. KUFE	
		Filing Date: December 11, 2003	Group: 1633
U.S. Patent Documents <i>See Page 1-2</i>	Foreign Patent Documents <i>See Page 2-3</i>	Other Art <i>See Page 3-23</i>	

U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.
	A24	5,998,148	12/07/99	Bennett <i>et al.</i>	435	6	04/08/99
	A25	6,020,363	02/01/00	Hirano <i>et al.</i>	514	456	12/17/98
	A26	6,054,438	04/25/00	Taylor-Papadimitriou <i>et al.</i>	514	44	06/01/95
	A27	6,074,841	06/13/00	Gearing <i>et al.</i>	435	69.1	11/19/96
	A28	6,222,020	04/24/01	Taylor-Papadimitriou <i>et al.</i>	530	395	06/01/95
	A29	6,589,921	07/08/03	Herrmann <i>et al.</i>	514	456	02/27/01
	A30	6,716,627	04/06/04	Dobie	435	375	12/20/01
	A31	60/308,307	07/27/01	Kufe			07/27/01
	A32	60/502,111	09/11/03	Jecminek <i>et al.</i>			09/11/03

Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Language
	B1	DE 19909251	08/26/99	Germany	German (English Abstract)
	B2	EP 1103623	07/01/98	Europe	English
	B3	WO 00/25827	05/11/00	WIPO	English
	B4	WO 00/34468	06/15/00	WIPO	English
	B5	WO 00/77031	12/21/00	WIPO	English
	B6	WO 01/12217	02/22/01	WIPO	English
	B7	WO 01/18035	03/15/01	WIPO	English
	B8	WO 01/57068	08/09/01	WIPO	English
	B9	WO 02/058450	08/01/02	WIPO	English
	B10	WO 02/31512	04/18/02	WIPO	English
	B11	WO 03/014303	02/20/03	WIPO	English

70153984.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)
ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /KH/

Form PTO-1449 (modified)		Atty. Docket No.: GENU:009USD1	Serial No.: 10/733,212
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant: Donald W. KUFE	
		Filing Date: December 11, 2003	Group: 1633
U.S. Patent Documents <i>See Page 1-2</i>	Foreign Patent Documents <i>See Page 2-3</i>	Other Art <i>See Page 3-23</i>	

Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Language
	B12	WO 03/088995	10/30/03	WIPO	English
	B13	WO 2004/044160	05/27/04	WIPO	English
	B14	WO 2004/092339	10/28/04	WIPO	English
	B15	WO 91/09867	07/11/99	WIPO	English
	B16	WO 93/20841	10/28/93	WIPO	English

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C1	European Search Report, issued in European Application No. 08005820.9, dated July 22, 2008.
	C2	"MUC-1/X mucin short variant," GenBank Accession No.: AAD10856, dated June 5, 2001
	C3	"MUC-1/Z mucin short variant," GenBank Accession No.: AAD10858, dated June 5, 2001.
	C4	"Mucin 1 precursor, non-repetitive splice from Y [validated] – human," GenBank Accession No.: S48146, dated April 20, 2000.
	C5	Abe <i>et al.</i> , "Characterization of cis-acting elements regulating transcription of the human DF3 breast carcinoma-associated antigen (MUC1) gene," <i>Proc. Natl. Acad. Sci. USA.</i> , 90:282-286, 1993.
	C6	Abe <i>et al.</i> , "Identification of a family of high molecular weight tumor-associated glycoproteins," <i>J. Immun.</i> , 139:257-261, 1987.
	C7	Abe <i>et al.</i> , "Sequence Analysis of the 5' region of the human DF3 breast carcinoma-associated antigen gene," <i>Bio. Biophys. Research Comm.</i> , 165:664-649, 1989.
	C8	Abe <i>et al.</i> , "Sodium butyrate induction of milk-related antigens in human MCF-7 breast carcinoma cells," <i>Cancer Res.</i> , 44:4574-4577, 1984.
	C9	Abe <i>et al.</i> , "Structural analysis of the DF3 human breast carcinoma-associated protein," <i>Cancer Res.</i> , 49:2834-2839, 1989.
	C10	Abe <i>et al.</i> , "Transcriptional regulation of DF3 gene expression in human MCF-7 breast carcinoma cells," <i>J. Cell. Physio.</i> , 143:226-231, 1990.

70153984.1

EXAMINER:**DATE CONSIDERED:**

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT - PTO-1449 (MODIFIED)

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /KH/

Form PTO-1449 (modified)		Atty. Docket No.: GENU:009USD1	Serial No.: 10/733,212
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant: Donald W. KUFE	
		Filing Date: December 11, 2003	Group: 1633
U.S. Patent Documents See Page 1-2	Foreign Patent Documents See Page 2-3	Other Art See Page 3-23	

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C11	Adams and Cory, "The Bcl-2 Protein Family: Arbiters of Cell Survival," <i>Science</i> , 281:1322-1326, 1998.
	C12	Agrawal and Kandimalla, "Antisense therapeutics: is it as simple as complementary base recognition?" <i>Molecular Medicine Today</i> , 6:72-81, 2000.
	C13	Akagi <i>et al.</i> , "CA19-9 epitope a possible marker for MUC-1/Y protein," <i>Int. J. Oncol.</i> , 18:1085-1091, 2001.
	C14	Apostolopoulos <i>et al.</i> , "Production of anti-breast cancer monoclonal antibodies using a glutathione-S-transferase-MUC1 bacterial fusion protein," <i>British J. Cancer.</i> , 67:713-720, 1993.
	C15	Arklie <i>et al.</i> , "Differentiation antigens expressed by epithelial cells in the lactating breast are also detectable in breast cancers," <i>Int. J. Cancer</i> , 28:23-29, 1981.
	C16	Ashkenazi and Dixit, "Apoptosis control by death and decoy receptors," <i>Curr. Opin. Cell Biol.</i> , 11:255-260, 1999.
	C17	Ashkenazi and Dixit, "Death Receptors: Signaling and Modulation," <i>Science</i> , 281:1305-1308, 1998.
	C18	Ashkenazi <i>et al.</i> , "Safety and antitumor activity of recombinant soluble Apo2 ligand," <i>J. Clin. Invest.</i> , 104:155-162, 1999.
	C19	Backstrom <i>et al.</i> , "Recombinant MUC1 mucin with a breast cancer-like O-glycosylation produced in large amounts in Chinese-hamster ovary cells," <i>Biochemical Journal</i> , 376:677-686, 2003.
	C20	Banerjee, "Omega amino acids in peptide design: incorporation into helices," <i>Biopolymers</i> , 39:769-77, 1996.
	C21	Barrett <i>et al.</i> , "PLU-1 nuclear protein, which is upregulated in breast cancer, shows restricted expression in normal human adult tissues: a new cancer/testis antigen?," <i>Int. J. Cancer</i> , 101:581-588, 2002.
	C22	Barry and Sharkey, "Observer reproducibility during computer-assisted planimetric measurements of nuclear features," <i>Hum. Pathol.</i> , 16:225-7, 1985.
	C23	Barry <i>et al.</i> , "Activation of programmed cell death (apoptosis) by cisplatin, other anticancer drugs, toxins and hyperthermia," <i>Biochemical Pharmacology</i> , 40:2353-2362, 1990.

70153984.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)
ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /KH/

Form PTO-1449 (modified)		Atty. Docket No.: GENU:009USD1	Serial No.: 10/733,212
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant: Donald W. KUFE	
		Filing Date: December 11, 2003	Group: 1633
U.S. Patent Documents <i>See Page 1-2</i>	Foreign Patent Documents <i>See Page 2-3</i>	Other Art <i>See Page 3-23</i>	

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C24	Baruch <i>et al.</i> , "Preferential expression of novel MUC1 tumor antigen isoforms in human epithelial tumors and their tumor-potentiating function," <i>Int. J. Cancer</i> , 71:741-749, 1997.
	C25	Baruch <i>et al.</i> , "The breast cancer-associated MUC1 gene generates both a receptor and its cognate binding protein," <i>Cancer Res.</i> , 59:1552-1561, 1999.
	C26	Bass, "The short answer," <i>Nature</i> , 411:428-429, 2001.
	C27	Bellgrau <i>et al.</i> , "A role for CD95 ligand in preventing graft rejection," <i>Nature</i> , 377:630-632, 1995.
	C28	Berger <i>et al.</i> , "Respiratory carcinoma cell lines: MUC genes and glycoconjugates," <i>American Journal of Respiratory Cell and Molecular Biology</i> , 20:500-510, 1999.
	C29	Bergeron <i>et al.</i> , "MAUB is a new mucin antigen associated with bladder cancer," <i>J. Biol. Chem.</i> , 271:6933-6940, 1996.
	C30	Beusen <i>et al.</i> , "Conformational mimicry: synthesis and solution conformation of a cyclic somatostatin hexapeptide containing a tetrazole cis amide bond surrogate," <i>Biopolymers</i> , 36:181-200, 1995.
	C31	Bird <i>et al.</i> , "Single-chain antigen-binding proteins," <i>Science</i> , 242:423-6, 1988.
	C32	Bodmer <i>et al.</i> , "Cysteine 230 is essential for the structure and activity of the cytotoxic ligand TRAIL," <i>J. Biol. Chem.</i> , 275:20632-20637, 2000.
	C33	Boldin <i>et al.</i> , "Involvement of MACH, a novel MORT1/FADD-interacting protease, in Fas/APO-1- and TNF receptor-induced cell death," <i>Cell</i> , 85:803-815, 1996.
	C34	Brossart <i>et al.</i> , "Identification of HLA-A2-restricted T-cell epitopes derived from MUC1 tumor antigen for broadly applicable vaccine therapies," <i>Blood</i> , 93:4309-4317, 1999.
	C35	Brunner <i>et al.</i> , " <i>pangolin</i> encodes a Lef-1 homologue that acts downstream of Armadillo to transduce the Wntless signal in <i>Drosophila</i> ," <i>Nature</i> , 385:829-33, 1997.
	C36	Bunz, "Cell death and cancer therapy," <i>Curr. Opin. Pharmacol.</i> , 1:337-341, 2001.
	C37	Burchell <i>et al.</i> , "A short sequence, within the amino acid tandem repeat of a cancer-associated mucin, contains immunodominant epitopes," <i>Int. J. Cancer</i> , 44:691-696, 1989.

70153984.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT - PTO-1449 (MODIFIED)
ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /KH/

Form PTO-1449 (modified)		Atty. Docket No.: GENU:009USD1	Serial No.: 10/733,212
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant: Donald W. KUFE	
		Filing Date: December 11, 2003	Group: 1633
U.S. Patent Documents <i>See Page 1-2</i>	Foreign Patent Documents <i>See Page 2-3</i>	Other Art <i>See Page 3-23</i>	

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C38	Burchell <i>et al.</i> , "Development and characterization of breast cancer reactive monoclonal antibodies directed to the core protein of the human milk mucin," <i>Cancer Res.</i> , 47:5476-5482, 1987.
	C39	Burns and El-Deiry, "Identification of inhibitors of TRAIL-induced death (ITIDs) in the TRAIL-sensitive colon carcinoma cell line SW480 using a genetic approach," <i>J. Biol. Chem.</i> , 276:37879-37886, 2001.
	C40	Busfield <i>et al.</i> , "Characterization of a neuregulin-related gene, <i>Don-1</i> , that is highly expressed in restricted regions of the cerebellum and hippocampus," <i>Mol. Cell. Biol.</i> , 17:4007-4014, 1997.
	C41	Cawley <i>et al.</i> , "Epidermal growth factor-toxin A chain conjugates: EGF-Ricin A is a potent toxin while EGF-Diphtheria fragment A is nontoxic," <i>Cell</i> , 22:563-570, 1980.
	C42	Chang <i>et al.</i> , "Artificial hybrid protein containing a toxic protein fragment and a cell membrane receptor-binding moiety in a disulfide conjugate," <i>J. Biol. Chem.</i> , 252:1515-1522, 1977.
	C43	Chang <i>et al.</i> , "Ligands for ErbB-family receptors encoded by a neuregulin-like gene," <i>Nature</i> , 387:509-512, 1997.
	C44	Chaudhary <i>et al.</i> , "A rapid method of cloning functional variable-region antibody genes in <i>Escherichia coli</i> as single-chain immunotoxins," <i>Proc. Natl. Acad. Sci. U.S.A.</i> , 87:1066-70, 1990.
	C45	Chaudhary <i>et al.</i> , "Activity of a recombinant fusion protein between transforming growth factor type alpha and <i>Pseudomonas</i> toxin," <i>Proc. Natl. Acad. Sci. USA</i> , 84:4538-4542, 1987.
	C46	Ciborowski <i>et al.</i> , "Screening of anti-MUC1 antibodies for reactivity with native (ascites) and recombinant (baculovirus) MUC1 and for blocking MUC1 specific cytotoxic T-lymphocytes," <i>Tumor Biology</i> , 19:147-151, 1998.
	C47	Console <i>et al.</i> , "Antennapedia and HIV transactivator of transcription (TAT) "protein transduction domains" promote endocytosis of high molecular weight cargo upon binding to cell surface glycosaminoglycans," <i>J. Biol. Chem.</i> , 278 :35109-14, 2003.
	C48	Creagan <i>et al.</i> , "Phase III clinical trial of the combination of cisplatin, dacarbazine, and carmustine with or without tamoxifen in patients with advanced malignant melanoma," <i>J. Clin. Oncol.</i> , 17:1884-1890, 1999.
	C49	Croghan <i>et al.</i> , "Tissue distribution of an epithelial and tumor-associated antigen recognized by monoclonal antibody F36/22," <i>Cancer Res.</i> , 43:4980-4988, 1983.

70153984.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)
ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /KH/

Form PTO-1449 (modified)		Atty. Docket No.: GENU:009USD1	Serial No.: 10/733,212
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant: Donald W. KUFE	
		Filing Date: December 11, 2003	Group: 1633
U.S. Patent Documents <i>See Page 1-2</i>	Foreign Patent Documents <i>See Page 2-3</i>	Other Art <i>See Page 3-23</i>	

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C50	Cunningham <i>et al.</i> , "Calreticulin binding and other biological activities of survival peptide Y-P30 including effects of systemic treatment of rats," <i>Exp. Neurol.</i> , 163:457-468, 2000.
	C51	Cunningham <i>et al.</i> , "Identification of a survival-promoting peptide in medium conditioned by oxidatively stressed cell lines of nervous system origin," <i>J. Neurosci.</i> , 18:7047-7060, 1998.
	C52	Cunningham <i>et al.</i> , "Identification of the human cDNA for new survival/evasion peptide (DSEP): studies in vitro and in vivo of overexpression by neural cells," <i>Exp. Neurol.</i> , 177:32-39, 2002.
	C53	Daniel and Reynolds, "The catenin p120(ctn) interacts with Kaiso, a novel BTB/POZ domain zinc finger transcription factor," <i>Mol. Cell. Biol.</i> , 19:3614-23, 1999.
	C54	Datta <i>et al.</i> , "Overexpression of Bcl-XL by cytotoxic drug exposure confers resistance to ionizing radiation-induced internucleosomal DNA fragmentation," <i>Cell Growth Differ.</i> , 6:363-370, 1995.
	C55	Dawson <i>et al.</i> , "Synthesis of proteins by native chemical ligation," <i>Science</i> , 266:776-779, 1994.
	C56	Deng <i>et al.</i> , "TRAIL-induced apoptosis requires Bax-dependent mitochondrial release of Smac/DIABLO," <i>Genes Dev.</i> , 16:33-45, 2002.
	C57	Derossi <i>et al.</i> , "Cell internalization of the third helix of the Antennapedia homeodomain is receptor-independent," <i>J Biol. Chem.</i> , 271:18188-93, 1996.
	C58	Derossi <i>et al.</i> , "The third helix of the Antennapedia homeodomain translocates through biological membranes," <i>J Biol. Chem.</i> , 269:10444-50, 1994.
	C59	Deveraux and Reed, "IAP family proteins--suppressors of apoptosis," <i>Genes Dev.</i> , 13:239-52, 1999.
	C60	Dillman, "Antibodies as cytotoxic therapy," <i>J. Clin. Oncology</i> , 12:1497-1515, 1994.
	C61	Doyle, "Crystal structures of a complexed and peptide-free membrane protein-binding domain: molecular basis of peptide recognition by PDZ," <i>Cell</i> , 85:1067-76, 1996.
	C62	Drucker <i>et al.</i> , "Tamoxifen enhances apoptotic effect of cisplatin on primary endometrial cell cultures," <i>Anticancer Research</i> , 23:1549-1554, 2003.
	C63	Du <i>et al.</i> , "Smac, a Mitochondrial Protein that Promotes Cytochrome c-Dependent Caspase Activation by Eliminating IAP Inhibition," <i>Cell</i> , 102:33-42, 2000.

70153984.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)
ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /KH/

Form PTO-1449 (modified)		Atty. Docket No.: GENU:009USD1	Serial No.: 10/733,212
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant: Donald W. KUFE	
		Filing Date: December 11, 2003	Group: 1633
U.S. Patent Documents <i>See Page 1-2</i>	Foreign Patent Documents <i>See Page 2-3</i>	Other Art <i>See Page 3-23</i>	

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C64	Elbashir <i>et al.</i> , "Analysis of gene function in somatic mammalian cells using small interfering RNAs," <i>Methods</i> , 26:199-213, 2002.
	C65	Elbashir <i>et al.</i> , "Functional anatomy of siRNAs for mediating efficient RNAi in <i>Drosophila melanogaster</i> embryo lysate," <i>EMBO Journal</i> , 20:6877-6888, 2001.
	C66	Elbashir <i>et al.</i> , "RNA interference is mediated by 21- and 22-nucleotide RNAs," <i>Genes and Development</i> , 15:188-200, 2001.
	C67	Elliot and O'Hare, "Intercellular trafficking and protein delivery by a herpesvirus structural protein," <i>Cell</i> , 88:223-33, 1997.
	C68	Elmqvist <i>et al.</i> , "VE-cadherin-derived cell-penetrating peptide, pVEC, with carrier functions," <i>Exp. Cell Res.</i> , 269:237-44, 2001.
	C69	Emoto <i>et al.</i> , "Proteolytic activation of protein kinase C delta by an ICE-like protease in apoptotic cells," <i>EMBO J.</i> , 14:6148-6156, 1995.
	C70	Faivre <i>et al.</i> , "Supraadditive effect of 2',2'-difluorodeoxycytidine (gemcitabine) in combination with oxaliplatin in human cancer cell lines," <i>Cancer Chemother. Pharmacol.</i> , 44:117-123, 1999.
	C71	Feigl, "2,8-Dimethyl-4-(carboxymethyl)-6-(aminomethyl)phenoxathiin S-Dioxide: An Organic Substitute for the beta-Turn in Peptides," <i>J. Amer. Chem. Soc.</i> , 108:181-2, 1986.
	C72	Finn <i>et al.</i> , "MUC-1 Epithelial Tumor Mucin-Based Immunity and Cancer Vaccines," <i>Immunol. Rev.</i> , 145:61-89, 1995.
	C73	Fontenot <i>et al.</i> , "Biophysical characterization of one-, two-, and three-tandem repeats of human musin (muc-1) protein core," <i>Cancer Research</i> , 53:5386-5394, 1993.
	C74	Frankel and Pabo, "Cellular uptake of the tat protein from human immunodeficiency virus," <i>Cell</i> , 55:1189-93, 1989.
	C75	French and Tschopp, "Inhibition of Death Receptor Signaling by FLICE-inhibitory Protein as a Mechanism for Immune Escape of Tumors," <i>J. Exp. Med.</i> , 190:891-893, 1999.
	C76	Futaki <i>et al.</i> , "Arginine-rich peptides. An abundant source of membrane-permeable peptides having potential as carriers for intracellular protein delivery," <i>J. Biol. Chem.</i> , 276 :5836-40, 2001.
	C77	Gendler <i>et al.</i> , "A highly immunogenic region of a human polymorphic epithelial mucin expressed by carcinomas is made up of tandem repeats," <i>J. Biol. Chem.</i> , 263:12820-12823, 1988.

70153984.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)
ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /KH/

Form PTO-1449 (modified)		Atty. Docket No.: GENU:009USD1	Serial No.: 10/733,212
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant: Donald W. KUFE	
		Filing Date: December 11, 2003	Group: 1633
U.S. Patent Documents <i>See Page 1-2</i>	Foreign Patent Documents <i>See Page 2-3</i>	Other Art <i>See Page 3-23</i>	

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C78	Gendler <i>et al.</i> , "Molecular cloning and expression of human tumor-associated polymorphic epithelial mucin," <i>J. Biol. Chem.</i> , 265:15286-15293, 1990.
	C79	George, D.G. et al., "Chapter 12. Current Methods in Sequence Comparison and Analysis," in: <i>Macromolecular Sequencing and Synthesis. Selected Methods and Applications</i> , Alan R. Liss, Inc., pp. 127-149 (1988).
	C80	Gopalakrishnan <i>et al.</i> , "Application of Micro Arrayed Compound Screening (microARCS) to identify inhibitors of caspase-3," <i>J. Biomol. Screen.</i> , 7:317-23, 2002.
	C81	Green and Loewenstein, "Autonomous functional domains of chemically synthesized human immunodeficiency virus tat trans-activator protein," <i>Cell</i> , 55:1179-88, 1989.
	C82	Griffith <i>et al.</i> , "CD95-Induced Apoptosis of Lymphocytes in an Immune Privileged Site Induces Immunological Tolerance," <i>Immunity</i> , 5:7-16, 1996.
	C83	Gross <i>et al.</i> , "Caspase cleaved BID targets mitochondria and is required for cytochrome c release, while BCL-XL prevents this release but not tumor necrosis factor-R1/Fas death," <i>J. Biol. Chem.</i> , 274:1156-1163, 1999.
	C84	Gutierrez <i>et al.</i> , "Gene therapy for cancer," <i>The Lancet</i> , 339:715-721, 1992.
	C85	Haim <i>et al.</i> , "Dexamethasone, cytarabine, ifosfamide, and cisplatin as salvage therapy in Non-Hodgkin lymphoma," <i>Am. J. Clin. Oncol.</i> , 22:47-50, 1999.
	C86	Hammond <i>et al.</i> , "Post-transcriptional gene silencing by double-stranded RNA," <i>Nature Genetics</i> , 2:110-119, 2001.
	C87	Hanson <i>et al.</i> , "MUC1 expression in primary breast cancer: the effect of tamoxifen treatment," <i>Breast Cancer Research and Treatment</i> , 67:215-222, 2001.
	C88	Harborth <i>et al.</i> , "Identification of essential genes in cultured mammalian cells using small interfering RNAs," <i>J. Cell Science</i> , 114:4557-4565, 2001.
	C89	Harlow and Lane, "Antibodies, A Lab Manual," Cold Spring Harbor, 1988.
	C90	Harris et al., "Therapeutic antibodies – the coming of age," <i>Tibtech</i> , 11:12-44, 1993.
	C91	Harrison, "Peptide-surface association: the case of PDZ and PTB domains," <i>Cell</i> , 86:341-343, 1996.

70153984.1

EXAMINER:**DATE CONSIDERED:**

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)
ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /KH/

Form PTO-1449 (modified)		Atty. Docket No.: GENU:009USD1	Serial No.: 10/733,212
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant: Donald W. KUFE	
		Filing Date: December 11, 2003	Group: 1633
U.S. Patent Documents <i>See Page 1-2</i>	Foreign Patent Documents <i>See Page 2-3</i>	Other Art <i>See Page 3-23</i>	

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C92	Hayes <i>et al.</i> , "Comparison of circulating CA15-3 and carcinoembryonic antigen levels in patients with breast cancer," <i>J. Clin. Oncol.</i> , 4:1542-1550, 1986.
	C93	Hayes <i>et al.</i> , "Genetically determined polymorphism of the circulating human breast cancer-associated DF3 antigen," <i>Blood</i> , 71:436-440, 1998.
	C94	Herr and Debatin, "Cellular stress response and apoptosis in cancer therapy," <i>Blood</i> , 98:2603-2614, 2001.
	C95	Higashiyama <i>et al.</i> , "A novel brain-derived member of the epidermal growth factor family that interacts with ErbB3 and ErbB4," <i>J. Biochem.</i> , 122:675-680, 1997.
	C96	Higgins, "Comparison of the solution conformations of a human immunodeficiency virus peptidomimetic and its retro-inverso isomer using ¹ H NMR spectroscopy," <i>J. Pept. Res.</i> , 50:421-35, 1997.
	C97	Hilkens <i>et al.</i> , "Biosynthesis of MAM-6, an epithelial sialomucin," <i>J. Biol. Chem.</i> , 263:4215-4222, 1988.
	C98	Hilkens <i>et al.</i> , "Complexity of MAM-6, an epithelial sialomucin associated with carcinomas," <i>Cancer Res.</i> , 49:786-793, 1989.
	C99	Hilkens <i>et al.</i> , "Monoclonal antibodies against human milk-fat globule membranes detecting differentiation antigens of the mammary gland and its tumors," <i>Int. J. Cancer</i> , 34:197-206, 1984.
	C100	Hird <i>et al.</i> , "Adjuvant therapy of ovarian cancer with radioactive monoclonal antibody," <i>Br. J. Cancer</i> , 68:403-406, 1993.
	C101	Hopp, "Protein surface analysis. Methods for identifying antigenic determinants and other interaction sites," <i>J. Immunol. Methods</i> , 88:1-18, 1986.
	C102	Houghton <i>et al.</i> , "Monoclonal antibodies: potential applications to the treatment of cancer," <i>Seminars in Oncology</i> , 13:165-179, 1986.
	C103	Hruby <i>et al.</i> , "Design of peptides, proteins, and peptidomimetics in chi space," <i>Biopolymers</i> , 43:219-66, 1997.
	C104	Hug <i>et al.</i> , "Liposomes for the transformation of eukaryotic cells," <i>Biochem. Biophys. Acta.</i> , 1097:1-17, 1991.

70153984.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)
ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /KH/

Form PTO-1449 (modified)		Atty. Docket No.: GENU:009USD1	Serial No.: 10/733,212
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant: Donald W. KUFE	
		Filing Date: December 11, 2003	Group: 1633
U.S. Patent Documents <i>See Page 1-2</i>	Foreign Patent Documents <i>See Page 2-3</i>	Other Art <i>See Page 3-23</i>	

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C105	Hull <i>et al.</i> , "Oligosaccharide differences in the DF3 sialomucin antigen from normal human milk and the BT-20 human breast carcinomas cell line," <i>Cancer Commun.</i> , 1:261-267, 1989.
	C106	Hunt and Evans, "Till Death Us Do Part," <i>Science</i> , 293:1784-1785, 2001.
	C107	Huston <i>et al.</i> , "Protein engineering of antibody binding sites: recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in <i>Escherichia coli</i> ," <i>Proc. Natl. Acad. Sci U.S.A.</i> , 85:5879-83, 1988.
	C108	Hymowitz <i>et al.</i> , "Triggering cell death: the crystal structure of Apo2L/TRAIL in a complex with death receptor 5," <i>Mol. Cell.</i> , 4:563-571, 1999.
	C109	Irmeler <i>et al.</i> , "Inhibition of death receptor signals by cellular FLIP," <i>Nature</i> , 388:190-195, 1997.
	C110	Itzkowitz <i>et al.</i> , "Sialosyl-Tn. A novel mucin antigen associated with prognosis in colorectal cancer patients," <i>Cancer</i> , 66:1960-6, 1990.
	C111	Jaattela <i>et al.</i> , "Bcl-x and Bcl-2 inhibit TNF and Fas-induced apoptosis and activation of phospholipase A2 in breast carcinoma cells," <i>Oncogene</i> , 10:2297-2305, 1995.
	C112	Jawhari <i>et al.</i> , "Up-regulated cytoplasmic expression, with reduced membranous distribution, of the src substrate p120(ctn) in gastric carcinoma," <i>J. Pathol.</i> 189:180-5, 1999.
	C113	Jen <i>et al.</i> , "Suppression of gene expression by targeted disruption of messenger RNA: available options and current strategies," <i>Stem Cells</i> , 18:307-319, 2000.
	C114	Jin <i>et al.</i> , "CIAP1 and the serine protease HTRA2 are involved in a novel p53-dependent apoptosis pathway in mammals," <i>Genes Dev.</i> , 17:359-67, 2003.
	C115	Julian and Carson, "Formation of MUC1 metabolic complex is conserved in tumor-derived and normal epithelial cells," <i>Biochem. Biophys. Res. Commun.</i> , 293:1183-1190, 2002.
	C116	Kahn <i>et al.</i> , "Nonpeptide Mimetics of beta-Turns: A Facile Oxidative Intramolecular Cycloaddition of an Azodicarbonyl System," <i>J. Amer. Chem. Soc.</i> , 110:1638-9, 1988.
	C117	Kahn, "The design and synthesis of mimetics of peptide beta-turns," <i>J. Molec. Recognition</i> , 1:75-9, 1988.
	C118	Kalofonos <i>et al.</i> , "Kinetics, quantitative analysis and radioimmunolocalisation using indium-111-HMFG1 monoclonal antibody in patients with breast cancer," <i>Cr. J. Cancer</i> , 59:939-942, 1989.

70153984.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT - PTO-1449 (MODIFIED)
ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /KH/

Form PTO-1449 (modified)		Atty. Docket No.: GENU:009USD1	Serial No.: 10/733,212
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant: Donald W. KUFE	
		Filing Date: December 11, 2003	Group: 1633
U.S. Patent Documents <i>See Page 1-2</i>	Foreign Patent Documents <i>See Page 2-3</i>	Other Art <i>See Page 3-23</i>	

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C119	Kalofonos <i>et al.</i> , "Radioimmunoschintigraphy in patients with ovarian cancer," <i>Acta Oncologica</i> , 38:629-634, 1999.
	C120	Karlsson <i>et al.</i> , "A genetic polymorphism of a human urinary mucin," <i>Ann. Hum. Genet.</i> , 47:263, 1983.
	C121	Karvinen <i>et al.</i> , "Homogeneous time-resolved fluorescence quenching assay (LANCE) for caspase-3," <i>J. Biomol. Screen.</i> , 7:223-31, 2002.
	C122	Kataoka <i>et al.</i> , "FLIP prevents apoptosis induced by death receptors but not by perforin/granzyme B, chemotherapeutic drugs, and gamma irradiation," <i>J. Immunol.</i> , 161:3936-3942, 1998.
	C123	Kayagaki <i>et al.</i> , "Metalloproteinase-mediated release of human Fas ligand," <i>J. Exp. Med.</i> , 182:1777-1783, 1995.
	C124	Kemp and Stites, "A convenient preparation of derivatives of 3(s)-amino-109(r)-carboxy-1,6-diazacyclodeca-2,7-dione the dilactam of L-alpha,gamma-diaminobutyric acid and d-glutamic acid: a beta-turn template," <i>Tet. Lett.</i> , 29:5057-60, 1988.
	C125	Kennerdell <i>et al.</i> , "Heritable gene silencing in <i>Drosophila</i> using double-stranded RNA," <i>Nature Biotechnology</i> , 17:896-898, 2000.
	C126	Kharbanda <i>et al.</i> , "Nuclear signaling induced by ionizing radiation involves colocalization of the activated p56/p53lyn tyrosine kinase with p34cdc2," <i>Cancer Res.</i> , 56:3617-3621, 1996.
	C127	Kischkel <i>et al.</i> , "Cytotoxicity-dependent APO-1 (Fas/CD95)-associated proteins form a death-inducing signaling complex (DISC) with the receptor," <i>EMBO J.</i> , 14:5579-5588, 1995.
	C128	Kluck <i>et al.</i> , "The Release of Cytochrome c from Mitochondria: A Primary Site for BCL-2 Regulation of Apoptosis," <i>Science</i> , 275:1132-1136, 1997.
	C129	Kotera <i>et al.</i> , "Humoral immunity against a tandem repeat epitope of human mucin MUC-1 in Ser from breat, pancreatic, and colon cancer patients," <i>Cancer Research</i> , 54:2856-2860, 1994.
	C130	Kroemer and Reed, "Mitochondrial control of cell death," <i>Nat. Med.</i> , 6:513-519, 2000.
	C131	Kufe <i>et al.</i> , "Differential reactivity of a novel monoclonal antibody (DF3) with human malignant versus benign breast tumors," <i>Hybridoma</i> , 3:223-232, 1984.
	C132	Kumar <i>et al.</i> , "Abrogation of the cell death response to oxidative stress by the c-Abl tyrosine kinase inhibitor STI571," <i>Mol. Pharmacol.</i> , 63:276-282, 2003.

70153984.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)
ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /KH/

Form PTO-1449 (modified)		Atty. Docket No.: GENU:009USD1	Serial No.: 10/733,212
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant: Donald W. KUFE	
		Filing Date: December 11, 2003	Group: 1633
U.S. Patent Documents <i>See Page 1-2</i>	Foreign Patent Documents <i>See Page 2-3</i>	Other Art <i>See Page 3-23</i>	

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C133	Kuppuswamy <i>et al.</i> , "Multiple functional domains of Tat, the trans-activator of HIV-1, defined by mutational analysis," <i>Nucl. Acids Res.</i> , 17:3551-61, 1989.
	C134	Lancaster <i>et al.</i> , "Structure and expression of the human polymorphic epithelial mucin cenge: an expressed VNTR unit," <i>Biochim. Biophys. Res. Comm.</i> , 173:1019-1029, 1990.
	C135	LaVallee <i>et al.</i> , "2-Methoxyestradiol up-regulates death receptor 5 and induces apoptosis through activation of the extrinsic pathway," <i>Cancer Research</i> , 63:468-475, 2003.
	C136	LeBlanc <i>et al.</i> , "Tumor-cell resistance to death receptor--induced apoptosis through mutational inactivation of the proapoptotic Bcl-2 homolog Bax," <i>Nat. Med.</i> , 8:274-281, 2002.
	C137	Lewis <i>et al.</i> , "Efficient delivery of siRNA for inhibition of gene expression in postnatal mice," <i>Nature Genetics</i> , 32:107-108, 2002.
	C138	Li <i>et al.</i> , "Cleavage of BID by Caspase 8 Mediates the Mitochondrial Damage in the FAS Pathway of Apoptosis," <i>Cell</i> , 94:491-501, 1998.
	C139	Li <i>et al.</i> , "Cytochrome c and dATP-Dependent Formation of Apaf-1/Caspase-9 Complex initiates and Apoptotic Protease Cascade," <i>Cell</i> , 91:479-489, 1997.
	C140	Li <i>et al.</i> , "DF3/MUC1 signaling in multiple myeloma cells is regulated by interleukin-7," <i>Cancer Biol. Ther.</i> , 2:187-193, 2003.
	C141	Li <i>et al.</i> , "Heregulin targets gamma-catenin to the nucleolus by a mechanism dependent on the DF3/MUC1 oncoprotein," <i>Mol. Cancer Res.</i> , 1:765-775, 2003.
	C142	Li <i>et al.</i> , "Human DF3/MUC1 carcinoma-associated protein functions as an oncogene," <i>Oncogene</i> , 22:6107-6110, 2003.
	C143	Li <i>et al.</i> , "The EGF receptor regulates interaction of the human DF3/MUC1 carcinoma antigen with c-SRC and β -catenin," <i>JBC Papers in Press</i> , manuscript C100359200, August 1, 2001.
	C144	Ligtenberg <i>et al.</i> , "Cell associated episialin is a complex containing two proteins derived from a common precursor," <i>J. Biol. Chem.</i> , 267:6171-6177, 1992.
	C145	Ligtenberg <i>et al.</i> , "Suppression of Cellular Aggregation by High Levels of Episialin," <i>Cancer Res.</i> , 52:2318-2324, 1992.
	C146	Lin <i>et al.</i> , "Inhibition of nuclear translocation of transcription factor NF-kappa B by a synthetic peptide containing a cell membrane-permeable motif and nuclear localization sequence," <i>J. Biol. Chem.</i> , 270:14255-8, 1995.

70153984.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT - PTO-1449 (MODIFIED)
ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /KH/

Form PTO-1449 (modified)		Atty. Docket No.: GENU:009USD1	Serial No.: 10/733,212
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant: Donald W. KUFE	
		Filing Date: December 11, 2003	Group: 1633
U.S. Patent Documents <i>See Page 1-2</i>	Foreign Patent Documents <i>See Page 2-3</i>	Other Art <i>See Page 3-23</i>	

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C147	Liu <i>et al.</i> , "Identification of a functionally important sequence in the cytoplasmic tail of integrin beta 3 by using cell-permeable peptide analogs," <i>Proc. Natl Acad. Sci. U.S.A.</i> , 93 :11819-24, 1996.
	C148	Liu <i>et al.</i> , "Induction of Apoptotic Program in Cell-Free Extracts: Requirement of dATP and Cyochrome c," <i>Cell</i> , 86:147-157, 1996.
	C149	Lundy <i>et al.</i> , "Monoclonal antibody DF3 correlates with tumor differentiation and hormone receptor status in breast cancer patients," <i>Breast Cancer Res. Treat.</i> , 5:269-276, 1985.
	C150	Luo <i>et al.</i> , "Bid, A Bcl2 Interacting Protein, Mediates Cytochrome c Release from Mitochondria in Response to Activation of Cell Surface Death Receptors," <i>Cell</i> , 94:481-490, 1998.
	C151	Makimura <i>et al.</i> , "Reducing hypothalamic AGRP by RNA interference increases metabolic rate and decreases body weight without influencing food intake," <i>BMC Neuroscience</i> , 3:18, 2002.
	C152	Manome <i>et al.</i> , "Enhancer sequences of the DF3 gene regulate expression of the herpes simplex virus thymidine kinase gene and confer sensitivity of human breast cancer cells to ganciclovir," <i>Cancer Research</i> , 54:5408-5413, 1994..
	C153	Maraveyas <i>et al.</i> , "Pharmacokinetics and toxicity of an Yttrium-90-CITC-DTPA-HMFG1 radioimmunoconjugate for intraperitoneal radioimmunotherapy of ovarian cancer," <i>Cancer</i> , 73:1067-1075, 1994.
	C154	Maraveyas <i>et al.</i> , "Pharmacokinetics, biodistribution, and dosimetry of specific and control radiolabeled monoclonal antibodies in patients with primary head and neck squamous cell carcinoma," <i>Cancer Research</i> , 55:1060-1069, 1995.
	C155	Mariani <i>et al.</i> , "Regulation of cell surface APO-1/Fas (CD95) ligand expression by metalloproteases," <i>Eur. J. Immunol.</i> , 25:2303-2307, 1995.
	C156	Marsters <i>et al.</i> , "A novel receptor for Apo2L/TRAIL contains a truncated death domain," <i>Curr. Biol.</i> , 7:1003-1006, 1997.
	C157	Martinez <i>et al.</i> , "Single-stranded antisense siRNAs guide target RNA cleavage in RNAi," <i>Cell</i> , 110:563-574, 2002.
	C158	Martins, "The serine protease Omi/HtrA2: a second mammalian protein with a Reaper-like function," <i>Cell Death Diff.</i> , 9:699-701, 2002.

70153984.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)
ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /KH/

Form PTO-1449 (modified)		Atty. Docket No.: GENU:009USD1	Serial No.: 10/733,212
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant: Donald W. KUFE	
		Filing Date: December 11, 2003	Group: 1633
U.S. Patent Documents <i>See Page 1-2</i>	Foreign Patent Documents <i>See Page 2-3</i>	Other Art <i>See Page 3-23</i>	

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C159	McGrath <i>et al.</i> , "The Yeast STE6 gene encodes a homologue of the mammalian multidrug resistance P-Glycoprotein," <i>Nature.</i> , 340:400, 1989.
	C160	McGuckin <i>et al.</i> , "Prognostic significance of MUC1 epithelial mucin expression in breast cancer," <i>Human Pathology</i> , 26:432-439, 1995.
	C161	Melani <i>et al.</i> , "Inhibition of proliferation by c-myc antisense oligodeoxynucleotides in colon adenocarcinoma cell lines that express c-myc," <i>Cancer Research</i> , 51:2897-2901, 1991.
	C162	Mi <i>et al.</i> , "Characterization of a class of cationic peptides able to facilitate efficient protein transduction in vitro and in vivo," <i>Mol. Ther.</i> , 2:339-47, 2000.
	C163	Milik <i>et al.</i> , "Lung lymphocyte elimination by apoptosis in the murine response to intratracheal particulate antigen," <i>J. Clin. Invest.</i> , 99:1082-1091, 1997.
	C164	Molenaar <i>et al.</i> , "XTcf-3 transcription factor mediates beta-catenin-induced axis formation in <i>Xenopus</i> embryos," <i>Cell</i> , 86:391-9, 1996.
	C165	Morris <i>et al.</i> , "A new peptide vector for efficient delivery of oligonucleotides into mammalian cells," <i>Nucleic Acid Res.</i> , 25:2730-6, 1997.
	C166	Muzio <i>et al.</i> , "FLICE, A Novel FADD-Homologous ICE/CED-3-like Protease, Is Recruited to the CD95 (fas/APO-1) Death-Inducing Signaling Complex," <i>Cell</i> , 85:817-827, 1996.
	C167	Nagai and Sato, "Synthesis of a bicyclic dipeptide with the shape of beta-turn central part," <i>Tet. Lett.</i> , 26:647-50, 1985.
	C168	Nagata, "Apoptosis by Death Factor," <i>Cell</i> , 88:355-365, 1997.
	C169	Nakashima <i>et al.</i> , "Inhibition of angiogenesis by a new isocoumarin, NM-3," <i>J. Antibiotics</i> , 52:426-428, 1999.
	C170	Neyfakh <i>et al.</i> , "Efflux-mediated multidrug resistance in <i>Bacillus subtilis</i> : similarities and dissimilarities with the mammalian system," <i>Proc. Natl. Acad. Sci. USA</i> , 88:4781-4785, 1991.
	C171	Nicholson <i>et al.</i> , "Radioimmunotherapy after chemotherapy compared to chemotherapy alone in the treatment of advanced ovarian cancer: a matched analysis," <i>Oncology Reports</i> 5:223-226, 1998.
	C172	Niethammer <i>et al.</i> , "CRIPT, a novel postsynaptic protein that binds to the third PDZ domain of PSD-95/SAP90," <i>Neuron</i> , 20:693-707, 1989.

70153984.1

EXAMINER:**DATE CONSIDERED:**

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)
ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /KH/

Form PTO-1449 (modified)		Atty. Docket No.: GENU:009USD1	Serial No.: 10/733,212
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant: Donald W. KUFE	
		Filing Date: December 11, 2003	Group: 1633
U.S. Patent Documents <i>See Page 1-2</i>	Foreign Patent Documents <i>See Page 2-3</i>	Other Art <i>See Page 3-23</i>	

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C173	Novak and Dedhar, "Signaling through beta-catenin and Lef/Tcf," <i>Cell Mol. Life Sci.</i> , 523-37, 1999.
	C174	Obermair <i>et al.</i> , "Expression of MUC1 splice variants in benign and malignant ovarian tumours," <i>Int. J. Cancer</i> , 100:166-171, 2002.
	C175	Oehlke <i>et al.</i> , "Cellular uptake of an alpha-helical amphipathic model peptide with the potential to deliver polar compounds into the cell interior non-endocytically," <i>Biochim. Biophys. Acta.</i> , 1414: 127-39, 1998.
	C176	Okazaki <i>et al.</i> , "Downregulation of gastric mucin gene expression and its biosynthesis by dexamethasone in the human," <i>J. Clin. Gastroenterol.</i> , 27(suppl. 1):S91-S92, 1998.
	C177	Oosterkamp <i>et al.</i> , "Comparison of MUC-1 mucin expression in epithelial and non-epithelial cancer cell lines and demonstration of a new short variant form (MUC-1/Z)," <i>Int. J. Cancer</i> , 72:87-94, 1997.
	C178	Opalinska <i>et al.</i> , "Nucleic-acid therapeutics: basic principles and recent applications," <i>Nature Reviews Drug Discovery</i> , 1:503-514, 2002.
	C179	Orkin Report & Recommendations of The Panel to Assess the NIH Investment in Research on Gene Therapy, 1995.
	C180	Padrón <i>et al.</i> , "Selective cell kill of the combination of gemcitabine and cisplatin in multilayered postconfluent tumor cell cultures," <i>Anti-Cancer Drugs</i> , 10:445-452, 1999.
	C181	Pan <i>et al.</i> , "An Antagonist Decoy Receptor and a Death Domain-Containing Receptor for TRAIL," <i>Science</i> , 277:815-818, 1997.
	C182	Pan <i>et al.</i> , "The Receptor for the Cytotoxic Ligand TRAIL," <i>Science</i> , 276:111-113, 1997.
	C183	Parrish <i>et al.</i> , "Functional anatomy of a dsRNA trigger: differential requirement for the two trigger strands in RNA interference," <i>Molecular Cell</i> , 8:1077-1087, 2000.
	C184	Parry <i>et al.</i> , "Identification of MUC1 proteolytic cleavage sites in vivo," <i>Biochem. Biophys. Res. Commun.</i> , 283:715-720, 2001.
	C185	Paszkiewicz-Gadek <i>et al.</i> , "Biosynthesis of MUC1 mucin in human endometrial adenocarcinoma is modulated by estradiol and tamoxifen," <i>Gynecol. Endocrinol.</i> , 17:37-44, 2003.
	C186	Pavlovic <i>et al.</i> , "Targeting of non-small cell lung cancer using HMFG1- ^{99m} Tc monoclonal antibodies," <i>Med Pregl.</i> , 46 Suppl 1:26-28, 1993

70153984.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)
ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /KH/

Form PTO-1449 (modified)		Atty. Docket No.: GENU:009USD1	Serial No.: 10/733,212
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant: Donald W. KUFE	
		Filing Date: December 11, 2003	Group: 1633
U.S. Patent Documents <i>See Page 1-2</i>	Foreign Patent Documents <i>See Page 2-3</i>	Other Art <i>See Page 3-23</i>	

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C187	Perey <i>et al.</i> , "Tumor selective reactivity of a monoclonal antibody prepared against a recombinant peptide derived from the DF3 human breast carcinoma-associated antigen," <i>Cancer Research</i> , 52:2563-2568, 1992.
	C188	Perez <i>et al.</i> , "Antennapedia homeobox as a signal for the cellular internalization and nuclear addressing of a small exogenous peptide," <i>J. Cell. Sci.</i> , 102:717-22, 1992.
	C189	Pescarolo <i>et al.</i> , "A retro-inverso peptide homologous to helix 1 of c-Myc is a potent and specific inhibitor of proliferation in different cellular systems," <i>FASEB J.</i> , 15:31-3, 2001.
	C190	Pitti <i>et al.</i> , "Induction of Apoptosis by Apo-2 Ligand, a New Member of the Tumor Necrosis Factor Cytokine Family," <i>J. Biol. Chem.</i> , 271:12687-12690, 1996.
	C191	Pooga <i>et al.</i> , "Cell penetrating PNA constructs regulate galanin receptor levels and modify pain transmission in vivo," <i>Nature Biotech.</i> , 16 :857-61, 1998.
	C192	Porowska <i>et al.</i> , "MUC1 expression in human breast cancer cells is altered by the factors affecting cell proliferation," <i>Neoplasma</i> , 49:104-109, 2002.
	C193	Porter <i>et al.</i> , "A neural survival factor is a candidate oncogene in breast cancer," <i>Proc. Natl. Acad. Sci. USA</i> , 100:10931-10936, 2003.
	C194	Price <i>et al.</i> , "Immunological and structural features of the protein core of human polymorphic epithelial mucin," <i>Molecular Immunology</i> , 27:795-802, 1990.
	C195	Price <i>et al.</i> , "Summary report on the ISOBM TD-4 workshop: analysis of 56 monoclonal antibodies against the MUC1 mucin," San Diego, California, November 17-23, 1996, <i>Tumor Biol.</i> , 19:sup. 1:1-20, 1998.
	C196	Reddish <i>et al.</i> , "Pre-immunotherapy serum CA27.29 (MUC-1) mucin level and CD69+ lymphocytes correlate with effects of Theratope sialyl-Tn-KLH cancer vaccine in active specific immunotherapy," <i>Cancer Immunol. Immunother.</i> , 42:303-9, 1996.
	C197	Reich <i>et al.</i> , "Small interfering RNA (siRNA) targeting VEGF effectively inhibits ocular neovascularization in a mouse model," <i>Molecular Vision</i> , 9:210-216, 2003.
	C198	Ren <i>et al.</i> , "Protein kinase C delta regulates function of the DF3/MUC1 carcinoma antigen in beta-catenin signaling," <i>J. Biol. Chem.</i> , 277:17616-17622, 2002.
	C199	Reynolds <i>et al.</i> , "Identification of a new catenin: the tyrosine kinase substrate p120cas associates with E-cadherin complexes," <i>Mol. Cell. Biol.</i> , 14:8333-42, 1994.

70153984.1

EXAMINER:**DATE CONSIDERED:**

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT - PTO-1449 (MODIFIED)
ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /KH/

Form PTO-1449 (modified)		Atty. Docket No.: GENU:009USD1	Serial No.: 10/733,212
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant: Donald W. KUFE	
		Filing Date: December 11, 2003	Group: 1633
U.S. Patent Documents <i>See Page 1-2</i>	Foreign Patent Documents <i>See Page 2-3</i>	Other Art <i>See Page 3-23</i>	

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C200	Reynolds <i>et al.</i> , "Transformation-specific tyrosine phosphorylation of a novel cellular protein in chicken cells expressing oncogenic variants of the avian cellular src gene," <i>Mol. Cell. Biol.</i> , 9:629-38, 1989.
	C201	Rousselle <i>et al.</i> , "New advances in the transport of doxorubicin through the blood-brain barrier by a peptide vector-mediated strategy," <i>Mol. Pharmacol.</i> , 57 :679-86, 2000.
	C202	Ruben <i>et al.</i> , "Structural and functional characterization of human immunodeficiency virus tat protein," <i>J. Virol.</i> , 63(1):1-8, 1989.
	C203	Sato <i>et al.</i> , "FAP-1: A Protein Tyrosine Phosphatase That Associates with Fas," <i>Science</i> , 268:411-415, 1995.
	C204	Scaffidi <i>et al.</i> , "Differential Modulation of Apoptosis Sensitivity in CD95 Type I and Type II Cells," <i>J. Biol. Chem.</i> , 274:22532-22538, 1999.
	C205	Schneider <i>et al.</i> , "Mutagenesis and selection of PDZ domains that bind new protein targets," <i>Nat. Biotech.</i> , 17:170-5, 1998.
	C206	Schroeder <i>et al.</i> , "Transgenic MUC1 interacts with epidermal growth factor receptor and correlates with mitogen-activated protein kinase activation in the mouse mammary gland," <i>J Biol Chem</i> , 276:13057-13064, 2001.
	C207	Schultz <i>et al.</i> , "Specific interactions between the syntrophin PDZ domain and voltage-gated sodium channels," <i>Nat. Struct. Biol.</i> , 5:19-24, 1998.
	C208	Schumacher <i>et al.</i> , "Immunoscintigraphy with positron emission tomography: Gallium-68 chelate imaging of breast cancer pretargeted with bispecific anti-MUC1/anti-Ga chelate antibodies," <i>Cancer Research</i> , 61:3712-3717, 2001.
	C209	Sekine <i>et al.</i> , "Purification and characterization of a high molecular weight glycoprotein detectable in human milk and breast carcinomas," <i>J. Immunol.</i> , 135:3610-3615, 1985.
	C210	Sherman <i>et al.</i> , "Ionizing radiation regulates expression of the c-jun protooncogene," <i>Proc. Natl. Acad. Sci. USA</i> , 87:5663-5666, 1990.
	C211	Shimazui <i>et al.</i> , "Prognostic value of cadherin-associated molecules (alpha-, beta-, and gamma-catenins and p120cas) in bladder tumors," <i>Cancer Res.</i> , 56:4154-8, 1996.
	C212	Siddiqui <i>et al.</i> , "Isolation and sequencing of a cDNA coding for the human DF3 breast carcinoma-associated antigen," <i>Proc. Natl. Acad. Sci. USA</i> , 85:2320-2323, 1988.

70153984.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)
ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /KH/

Form PTO-1449 (modified)	Atty. Docket No.: GENU:009USD1	Serial No.: 10/733,212
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)	Applicant: Donald W. KUFÉ	
	Filing Date: December 11, 2003	Group: 1633
U.S. Patent Documents See Page 1-2	Foreign Patent Documents See Page 2-3	Other Art See Page 3-23

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C213	Sloan <i>et al.</i> , "Distribution of epithelial membrane antigen in normal and neoplastic tissues and its value in diagnostic tumor pathology, <i>Cancer</i> , 47:1786-1795, 1981.
	C214	Smith and Waterman, "Comparison of Biosequences," <i>Adv. Appl. Math.</i> , 2:482-9, 1981.
	C215	Smith, "Design, Synthesis, and Crystal Structure of a Pyrrolinon-Based Peptidomimetic Possessing the Conformation of a beta-Strand: Potential Application to the Design of Novel Inhibitors of Proteolytic Enzymes," <i>J. Amer. Chem. Soc.</i> , 114:10672-4, 1992.
	C216	Songyang <i>et al.</i> , "Recognition of unique carboxyl-terminal motifs by distinct PDZ domains," <i>Science</i> , 275:73-7, 1997.
	C217	Soomets <i>et al.</i> , "Deletion analogues of transportan," <i>Biochim. Biophys. Acta</i> , 1467:165-176, 2000.
	C218	Spatola, "A Peptide Backbone Modifications," In: Chemistry and Biochemistry of Amino Acids, Peptides and Proteins, 7:267-357, Marcell Dekker, NY, 1983.
	C219	Srinivasan <i>et al.</i> , "Bcl-xL functions downstream of caspase-8 to inhibit Fas- and tumor necrosis factor receptor 1-induced apoptosis of MCF7 breast carcinoma cells," <i>J. Biol. Chem.</i> , 273:4523-4529, 1998.
	C220	Srinivasula <i>et al.</i> , "Autoactivation of procaspase-9 by Apaf-1-mediated oligomerization," <i>Mol. Cell</i> , 1:949-957, 1998.
	C221	Stennicke <i>et al.</i> , "Pro-caspase-3 is a major physiologic target of caspase-8," <i>J. Biol. Chem.</i> , 273:27084-27090, 1998.
	C222	Strous and Decker, "Mucin-Type Glycoproteins," <i>Crit. Rev. Biochem., Mol. Biol.</i> , 27:57-92, 1992.
	C223	Struhl, "Delection mapping a eukaryotic promoter," <i>Proc. Natl. Acad. Sci. USA</i> , 78:4461-4465, 1981.
	C224	Subbarao <i>et al.</i> , "pH-dependent bilayer destabilization by an amphipathic peptide," <i>Biochemistry</i> , 26:2964-2972, 1987.
	C225	Swallow <i>et al.</i> , "The human tumour-associated epithelial mucins are coded by an expressed hypervariable gene locus PUM," <i>Nature</i> , 328:82-84, 1987.
	C226	Takeichi, "Cadherins: a molecular family important in selective cell-cell adhesion," <i>Annu. Rev. Biochem.</i> , 59:237-52, 1990.

70153984.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)
ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /KH/

Form PTO-1449 (modified)		Atty. Docket No.: GENU:009USD1	Serial No.: 10/733,212
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant: Donald W. KUFE	
		Filing Date: December 11, 2003	Group: 1633
U.S. Patent Documents <i>See Page 1-2</i>	Foreign Patent Documents <i>See Page 2-3</i>	Other Art <i>See Page 3-23</i>	

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C227	Taylor <i>et al.</i> , "Antisense oligonucleotides: a systematic high-throughput approach to target validation and gene function determination," <i>Drug Discovery Today</i> , 4:562-567, 1999.
	C228	Timmer <i>et al.</i> , "Fas receptor-mediated apoptosis: a clinical application?" <i>J. Pathol.</i> , 196:125-134, 2002.
	C229	Tondini <i>et al.</i> , "Comparison of CA15-3 and carcinoembryonic antigen in monitoring the clinical course of patients with metastatic breast cancer," <i>Cancer Res.</i> , 48:4107-4112, 1988.
	C230	Tondini <i>et al.</i> , "Evaluation of monoclonal antibody DF3 conjugated with ricin as a specific immunotoxin for <i>in Vitro</i> purging of human bone marrow," <i>Cancer Research</i> , 50:1170-1175, 1990.
	C231	Topp <i>et al.</i> , "MUC-1 specific T-cells are present in multiple myeloma patients at high frequency after allogeneic transplantation buy may not mediated the graft versus myeloma effect," <i>Blood</i> , 100: page Abstract No. 5191, 2002.
	C232	Torchilin and Levchenko, "TAT-liposomes: a novel intracellular drug carrier," <i>Curr. Protein Pept. Sci.</i> , 4:133-40, 2003.
	C233	Tseng <i>et al.</i> , "Translocation of liposomes into cancer cells by cell-penetrating peptides penetratin and tat: a kinetic and efficacy study," <i>Mol. Pharmacol.</i> , 62:864-72, 2002.
	C234	van Hof <i>et al.</i> , "Biodistribution of 111Indium-labeled engineered human antibody CTMO1 in ovarian cancer patients: influence of protein dose," <i>Cancer Research</i> , 56:5179-5185, 1996.
	C235	Verhagen <i>et al.</i> , "Identification of DIABLO, a Mammalian Protein that Promotes Apoptosis by Binding to and Antagonizing IAP Proteins," <i>Cell</i> , 102:43-53, 2000.
	C236	Vermeer <i>et al.</i> , "Segregation of receptor and ligand regulates activation of epithelial growth factor receptor," <i>Nature</i> , 422:322-326, 2003.
	C237	Vives <i>et al.</i> , "A truncated HIV-1 Tat protein basic domain rapidly translocates through the plasma membrane and accumulates in the cell nucleus," <i>J. Biol. Chem.</i> , 272 :16010-7, 1997.
	C238	Vleck <i>et al.</i> , "Pseudorabies virus immediate-early gene overlaps with an oppositely oriented open reading frame: Characterization of their promoter and enhancer regions," <i>Virology</i> , 179:365,337, 1990.
	C239	Von Zonneveld <i>et al.</i> , "Type 1 plasminogen activator inhibitor gene: Functional analysis and glucocorticoid regulation of its promoter," <i>Proc. Natl. Acad. Sci. USA</i> , 85:5525-5529, 1988.

70153984.1

EXAMINER:**DATE CONSIDERED:**

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)
ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /KH/

Form PTO-1449 (modified)		Atty. Docket No.: GENU:009USD1	Serial No.: 10/733,212
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant: Donald W. KUFÉ	
		Filing Date: December 11, 2003	Group: 1633
U.S. Patent Documents <i>See Page 1-2</i>	Foreign Patent Documents <i>See Page 2-3</i>	Other Art <i>See Page 3-23</i>	

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C240	Walczak <i>et al.</i> , "TRAIL-R2: a novel apoptosis-mediating receptor for TRAIL," <i>EMBO J.</i> , 16:5386-5397, 1997.
	C241	Walczak <i>et al.</i> , "Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo," <i>Nat. Med.</i> , 5:157-163, 1999.
	C242	Waldmann, "Monoclonal antibodies in diagnosis and therapy," <i>Science</i> 252:1657-1662, 1991.
	C243	Walsh <i>et al.</i> , "Heterogeneity of MUC1 expression by human breast carcinoma cell lines <i>in vivo</i> and <i>in vitro</i> ," <i>Breast Cancer Research and Treatment</i> , 58:255-266, 2000.
	C244	Wang and El-Deiry, "TRAIL and apoptosis induction by TNF-family death receptors," <i>Oncogene</i> , 24:8628-8633, 2003.
	C245	Wender <i>et al.</i> , "The design, synthesis, and evaluation of molecules that enable or enhance cellular uptake: peptoid molecular transporters," <i>Proc. Natl. Acad. Sci., U.S.A.</i> , 97:13003-8, 2000.
	C246	Williams <i>et al.</i> , "Selective inhibition of growth factor-stimulated mitogenesis by a cell-permeable Grb2-binding peptide," <i>J. Biol. Chem.</i> , 272:22349-54, 1997.
	C247	Wreschner <i>et al.</i> , "Does a novel form of the breast cancer marker protein MUC1, act as receptor molecule that modulates signal transduction," In: <i>Antigen and Antibody Molecular Engineering in Breast Cancer Diagnosis and Treatment</i> , Ed. Ceriani Plenum Press, New York, pp. 17-26, 1994.
	C248	Xia <i>et al.</i> , "siRNA-mediated gene silencing in vitro and invivo," <i>Nature Biotechnology</i> , 20:1006-1010, 2002.
	C249	Xing <i>et al.</i> , "Synthetic peptides reactive with anti-human milk fat globule membrane monoclonal antibodies," <i>Cancer Research</i> , 50:89-96, 1990.
	C250	Xing <i>et al.</i> , "Effect of variations in peptide sequence on anti-human milk fat globule membrane antibody reactions," <i>Immunology</i> , 72:304-311, 1991.
	C251	Xing <i>et al.</i> , "Epitope mapping of anti-breast and anti-ovarian mucin monoclonal antibodies," <i>Molecular Immunology</i> , 29:641-650, 1992.
	C252	Xing <i>et al.</i> , "Monoclonal antibodies reactive with mucin expressed in breast cancer," <i>Immunol. Cell. Biol.</i> , 67:183-195, 1989.
	C253	Xing <i>et al.</i> , "Second generation anti-MUC1 peptide monoclonal antibodies," <i>Cancer Research</i> , 52:2310-2317, 1992.

70153984.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT - PTO 1449 (MODIFIED)
ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /KH/

Form PTO-1449 (modified)		Atty. Docket No.: GENU:009USD1	Serial No.: 10/733,212
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant: Donald W. KUFÉ	
		Filing Date: December 11, 2003	Group: 1633
U.S. Patent Documents See Page 1-2	Foreign Patent Documents See Page 2-3	Other Art See Page 3-23	

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C254	Yang <i>et al.</i> , "Prevention of Apoptosis by Bcl-2: Release of Cytochrome c from Mitochondria Blocked," <i>Science</i> , 275:1129-1132, 1997.
	C255	Yeh <i>et al.</i> , "Design of yeast-secreted albumin derivatives for human therapy: biological and antiviral properties of a serum albumin-CD4 genetic conjugate," <i>Proc. Natl. Acad. Sci. USA</i> , 89:1904-1908, 1992.
	C256	Zrihan-Licht <i>et al.</i> , "Characterization and molecular cloning of a novel MUC1 protein, devoid of tandem repeats, expressed in human breast cancer tissue," <i>Eur. J. Biochem.</i> , 224:787-795, 1994.
	C257	Office Communication, issued in United States Patent Application No. 10/032,786, dated February 26, 2003.
	C258	Office Communication, issued in United States Patent Application No. 10/032,786, dated July 2, 2003.
	C259	Alexander <i>et al.</i> , "Beta-catenin - A linchpin in colorectal carcinogenesis," <i>American Journal of Pathology</i> , 160:389-401, 2003.
	C260	Anderson, "Human Gene Therapy," <i>Nature</i> , 392(6679 Suppl.):25-30, 1998.
	C261	Anderson, "The current status of clinical gene therapy," <i>Human Gene Therapy</i> , 13:1261-1262, 2002.
	C262	Behrens <i>et al.</i> , "Functional interaction of Beta-catenin with the transcription factor LEF-1," <i>Letter to Nature</i> , 382:638-342, 1996.
	C263	Branch, "A good antisense molecule is hard to find," <i>TIBS</i> , 23:45-50, 1998.
	C264	Crooke, "Basic principles of antisense therapeutics," Springer-Verlag, NY, pages 1-50, 1998.
	C265	Crystal, "Transfer of genes to humans: Early lessons and obstacles to success," <i>Science</i> , 270:404-410, 1995.
	C266	Friedmann, "Overcoming the obstacles to gene therapy," <i>Scientific American</i> , 96-101, 1997.
	C267	Huber <i>et al.</i> , "Nuclear localization of Beta-catenin by interaction with transcription factor LEF-1," <i>Mech. Develop.</i> , 59:3-10, 1996.
	C268	Songyang <i>et al.</i> , "SH2 domains recognize specific phosphopeptide sequences," <i>Cell</i> , 72:767-778, 1993.

70153984.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)
ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /KH/

Form PTO-1449 (modified)		Atty. Docket No.: GENU:009USD1	Serial No.: 10/733,212
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant: Donald W. KUFE	
		Filing Date: December 11, 2003	Group: 1633
U.S. Patent Documents <i>See Page 1-2</i>	Foreign Patent Documents <i>See Page 2-3</i>	Other Art <i>See Page 3-23</i>	

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C269	Verma <i>et al.</i> , "Gene therapy – promises, problems and prospects," <i>Nature</i> , 389:239-242, 389.

70153984.1

EXAMINER: /Kevin Hill/

DATE CONSIDERED: 01/29/2009

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)
ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /KH/